Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous tumor-infiltrating lymphocytes + aldesleukin
- Development stage
- Phase 2
- Lead developer
- Iovance Biotherapeutics
- Modality
- Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
TIL + IL2 is an experimental adjuvant adoptive cell therapy regimen developed by Nantes University Hospital for the treatment of stage III melanoma. The therapy involves the ex vivo expansion of autologous tumor-infiltrating lymphocytes (TIL) harvested from a patient's resected lymph node. These expanded TILs are then re-infused into the patient alongside low-dose subcutaneous interleukin-2 (IL-2, aldesleukin) to promote T-cell survival and proliferation. Unlike many TIL protocols, this specific regimen does not utilize pre-infusion lymphodepletion. A Phase III trial (NCT00200577) evaluated this combination in patients with a single positive lymph node following surgery, though it failed to demonstrate a statistically significant improvement in disease-free survival compared to observation.
- Other names
- TIL + IL2TIL + IL-2Tumor Infiltrating Lymphocytes and Interleukin 2TIL and IL2 Adjuvant Therapy
02
Targets
IL2RB (IL-2 receptor beta chain)MHC I (MHC class I})pMHC-II (Peptide-major histocompatibility complex class II complex)
Beyond the preview
Go deeper on autologous tumor-infiltrating lymphocytes + aldesleukin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous tumor-infiltrating lymphocytes + aldesleukin.